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Human amniotic membrane (HAM) has been used as a biomaterial in various surgical procedures and exceeds some qualities
of common materials. We evaluated HAM as wound dressing for split-thickness skin-graft (STSG) donor sites in a swine model
(Part A) and a clinical trial (Part B). Part A: STSG donor sites in 4 piglets were treated with HAM or a clinically used conventional
polyurethane (PU) foil (𝑛 = 8 each). Biopsies were taken on days 5, 7, 10, 20, 40, and 60 and investigated immunohistochemically
for alpha-smooth muscle actin (𝛼SMA: wound contraction marker), von Willebrand factor (vWF: angiogenesis), Ki-67 (cell
proliferation), and laminin (basement membrane integrity). Part B: STSG donor sites in 45 adult patients (16 female/29 male) were
treated with HAM covered by PU foam, solely by PU foam, or PU foil/paraffin gauze (𝑛 = 15 each). Part A revealed no difference
in the rate of wound closure between groups. HAM showed improved esthetic results and inhibitory effects on cicatrization.
Angioneogenesis was reduced, and basement membrane formation was accelerated in HAM group. Part B: no difference in re-
epithelialization/infection rate was found. HAM caused less ichor exudation and less pruritus. HAM has no relevant advantage
over conventional dressings but might be a cost-effective alternative.
1. Introduction
Human amniotic membrane (HAM) is the inner layer of
the fetal membranes (the outer layer being formed by
the chorion) and has been investigated as an alternative
biomaterial for various purposes in reconstructive surgery
and wound-healing research since its initial description as
a transplantable material by Davis in 1910 [1]. In the 20th
century, it offered new perspectives, for example, in the
treatment of burn wounds, as shown in a 1977 clinical
study in which it was used as a dressing for second and
third degree burns in children, exhibiting superior qual-
ities when compared with conventional dressings [2]. In
another exemplary study in 1982, amniotic membranes were
used for the coverage of facial dermabrasions in thirty-
three patients. The results “were excellent” and revealed
“advantages of amniotic membranes over the other employed
dressing techniques” [3]. However, interest in HAM research
and clinical investigations diminished as a consequence of
the emerging awareness of AIDS and the consequent fear
of virus transmission in the 1980s. It was not before the
end of the 1990s that new methods for the processing and
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long-term storage (cryopreservation) of HAM were estab-
lished, and its use in wound care and reconstructive surgery
became a target of scientific interest again [4]. For example,
2308 HAM transplantations for ophthalmologic reconstruc-
tions were carried out in Germany in 2008 [5]. Trans-
plantation to the eye seems to be possible because of the
immune-privileged properties of HAM [6]. This feature
might also be an explanation for the lack of adverse reactions
following HAM transplantations noted in other studies [2].
Amniotic membrane has been demonstrated to function as a
tissue engineering scaffold material, for example, for corneal
epithelium reconstruction by means of transplantation of
epithelial cells on a lyophilized amniotic membrane (LAM)
[7]. Interestingly, HAM further seems to release factors with
antioncogenic potential, for example, for the inhibition of
prostate cancer cell growth [8].The combination of HAM (as
a feeder layer)with other antioncogenic agentsmight result in
synergetic effects and possibly in innovative potent materials
for cancer treatment. Horch et al. have recently stated that
the “synthesis of tissue engineering with innovative methods
of molecular biology and stem-cell technology may help
investigate and potentially modulate principal phenomena
of tumour growth and spreading, as well as tumour-related
angiogenesis” [9].
Recently, we have investigated the suitability of HAM as
part of a wound dressing for full-thickness skin-graft donor
sites in a porcine model and obtained promising results [10].
However, the usefulness of HAM as a dressing biomaterial
for split-thickness skin-graft (STSG) donor sites has not
been investigated yet. Commonly used dressing techniques
such as polyurethane (PU) film or foam dressings are beset
with disadvantages, such as the accumulation of blood and
wound secretions that make visual monitoring of the wound-
healing process difficult and imply the risk of uncontrollable
leakage and infection (Figure 1). They are also expensive
materials that cannot be afforded in all clinics, for example, in
developing countries. The purpose of this study has been to
evaluate the usefulness of HAM as an alternative biomaterial
for STSG-donor site coverage and to compare the results with
the commonly used PU foil and PU foam wound dressings
in order to test the null-hypothesis that HAM exhibits
superior qualities as a wound dressing when compared with
PU foil/foam dressings. This hypothesis is based on the
positive results obtained in previous clinical studies that
demonstrated the qualities of HAM in the treatment of burn
wounds and in ophthalmologic surgery and for the treatment
of full-thickness skin-graft donor sites.
2. Materials and Methods
2.1. Part A. Animal experiments were approved by the local
committee of animal welfare and by the local government
(AZ: 9.93.2.10.32.07.152, LANUV Recklinghausen). Four six-
month-old male Berlin minipigs (FA. Schlesier, Großerk-
mannsdorf, Germany) with initial body weights of 24–31 kg
were caged according to international principles of laboratory
animal care; water and food were available ad libitum.
Human placentas for the harvesting of HAM for use
in the animal experiment were obtained and processed as
Figure 1: Wound dressing of a split-thickness skin-graft donor site
defect (covered with PU foil) on the anterolateral thigh on the third
postoperative day. Note the accumulation of wound exudate, which
disturbs the clinical evaluation of reepithelialization. In addition, the
risk of uncontrolled leakage is high, as is patient discomfort.
Figure 2: Application of human amniotic membrane to a porcine
split-thickness skin-graft donor site defect.
previously described [10]. General anesthesia, intubation, and
perioperative management of the animals were carried out
according to previous protocols [11]. Until use, each HAM
sheet used in the animal experiment was kept moist by stor-
age in a sterile tube filled with a standard cryopreservation
medium containing dimethyl sulfoxide (DMSO) as described
earlier [10]. All HAM sheets for the animal experiment were
immediately transferred to the laboratory on the same facility
for processing (e.g., rinsing with sterile solution for removal
of blood, selection of avascular areas, cutting into square
pieces, and storage in DMSO cryopreservation medium) and
snap-frozen. Hence, growth factors within the membranes
were preserved.
Four square split-thickness skin-graft donor site defects
(5 × 5 cm) were created on the back of each of the animals
(sixteen wounds in total) with a dermatome (Nouvag GmbH,
Konstanz, Germany) to a depth of 0.2mm. Two of these
four defectswere randomly dressedwith cryopreservedHAM
(Figure 2), which were thawed 30 minutes before use in
a 28∘C water bath. Histological analysis of HAM revealed
stromal tissue (connected to the chorion) on the inner side
and an epithelial layer of cuboidal cells on the outer side. Both
sides are divided by a basement membrane. In the present
study, the smooth epithelial layer was identified by its glossy
surface. The epithelial side of the HAM was subsequently
placed onto the STSG-donor site defect surface. The two
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remaining defects were covered with a PU foil (3MTegaderm
Film, 3M, St. Paul, Minnesota, USA) as a control. Thus, a
total of eight defects were treated with HAM and a total of
eight defects with PU foil. After application to a STSG-donor
site, HAM was kept moist with an occlusive wound dressing.
For stabilization and protection of the wound dressings
against dirt, an additional cotton bandage (Rolta 10 cm ×
3m, Henry Schein Vet GmbH, Hamburg, Germany) and an
elastic tape (CoFlex 10 cm × 4.5m, Henry Schein Vet GmbH,
Hamburg,Germany)were applied.The elastic tapewas finally
fixed with adhesive tape so that the pigs were not able to
rip off the dressing. The bandages were renewed at least
after every second to third day according to requirements.
Animals were sacrificed 60 days after the surgical procedures
by intravenous administration of T61 (Bayer, Leverkusen,
Germany), at 1mL/5 kg body weight.
2.1.1. Evaluation of the Wound-Healing Process. The wound-
healing process was evaluated on postoperative days 5, 7, 10,
20, 40, and 60 by photodocumentation with a digital camera
(DMC-FZ4, Panasonic, Matsushita Electric Industrial Co.,
Ltd. Oska, Japan) and standardized with 6 mm tissue punch
biopsies (PFMAG, Carlsbad) on the respective days. Samples
were investigated histologically by hematoxylin/eosin (HE)
staining for general tissue architecture and thickness of the
epithelial layer (as an indicator of cicatrization/hypertrophy)
and immunohistochemical staining for alpha-smoothmuscle
actin (𝛼SMA, which is a marker for cicatrization), von
Willebrand factor (vWF, in order to determine angiogenesis
by the visualization of vessel walls), Ki-67 (as an indicator
of proliferating cells), and laminin (as a component of the
basement membrane, representing its integrity).
2.1.2. Histological and Immunohistochemical Analysis. Sam-
ples were stored in formalin (3.7%) for 24 hours and embed-
ded in paraffin, following which 4 mm thick sections were
cut with aHyraxM 55microtome (Zeiss, Jena, Germany) and
deparaffinized. Some of the sections were stained with hema-
toxylin/eosin (HE) in an automated staining system (Micro
HMS 740 Robot-Stainer, Thermo Fisher Scientific, Waltham,
USA) and analyzed with an AxioCam HRC microscope
(Zeiss) to visualize and characterize the tissue architecture
and epithelial thickness. The thickness of the epithelial layer
was determined on days 7 and 60 by 48 measurements per
biopsy at intervals of 0.05−1mm of the vertical distance from
the epithelial surface to the basement membrane by means
of “Leica Q Win” software (Leica Microsystems, Wetzlar,
Germany). The former time point represented the moment
of complete reepithelialization of all wounds, with the latter
corresponding to complete scar formation.
The remaining sections were immunohistochemically
stained with primary antibodies against 𝛼SMA (1 : 80,
mouse monoclonal to alpha-smooth muscle actin, Abcam,
Cambridge, UK), vWF (1 : 200, polyclonal rabbit anti-human
von Willebrand factor, Dako, Glostrup, Denmark), Ki-67
(1 : 50, monoclonal mouse anti-human Ki67-antigen, Dako),
and laminin (1 : 50, polyclonal rabbit antilaminin, Dako) by
using the Vectastain ABC Kit and a biotinylated secondary
antibody (1 : 200; Vector Laboratories, Burlingame, CA,
USA).The slides were incubated with peroxidase-conjugated
streptavidin (Vector). Diaminobenzidine was used as
a chromogen.The sections were counterstained with Mayer’s
hematoxylin (Bio Optica, Milan, Italy). Negative controls
without the primary antibodies were treated identically.
All staining was carried out in duplicate. The sections were
viewed, and images were captured with a Leitz Aristoplan
microscope (Leica, Wetzlar, Germany). Staining was scored
independently by two investigators as follows: in order to
determine the cellular basis for wound contractions and
scarring, the number of 𝛼-actin positive myofibroblasts,
which had been stained with the 𝛼SMA antibody, was
counted within five high-power fields (HPF), 10 sections
being evaluated in each group on each day.
Neovascularization was analyzed at the strongest phase of
proliferation of wound-healing on days 7 and 10 by means of
vWF staining. vWF is located in vessel walls and therefore
makes the determination of the number of vessels possible.
The proliferative activity of the epithelium was deter-
mined by the calculation of the proliferation index, which is
the quotient of the number of proliferating cells (stained by
the Ki-67 antibody) and the total number of basal cells. Five
HPF per biopsy were analyzed in each group on days 7 and 60
tomap themoment of highest proliferation in the early phase
of wound-healing and the proliferation status in scar tissue.
The integrity of the newly produced basement membrane
was determined by the staining of laminin, one of its integral
components. The presence of a basement membrane was
assessed in 10 sections of each biopsy as being either “not
visible” (−), “partly observable” (±), or “complete” (+).
2.2. Part B. The study protocol for the use of HAM was
approved by theDistrict Council and the local ethics commit-
tee (no. 3071/10; 1 February 2011). Operationswere carried out
in accordance with the Declaration of Helsinki. All patients
gave written informed consent. In the context of recon-
structive procedures, a standardized STSG of 0.4mm (0.016
inch) thickness was harvested from the anterolateral thigh
with a dermatome (Acculan 3Ti Dermatom, FA. Aesculap
AG, Tuttlingen, Germany) from 45 patients. All patients
had similar characteristics regarding their morbidity (neck
dissection, resection of an intraoral tumor/lesion such as
oral squamous cell carcinoma, defect reconstruction with
a microsurgically anastomosed free flap transplant such as
a radial forearm free flap, and closure of the donor site
with a STSG from the thigh). The STSG-donor sites of the
study group (𝑛 = 15) were covered with allogenic HAM
(group A), with at least 3mm overlapping and with the
chorion site of HAM toward the wound ground. Allogenic
HAM for the clinical study was fabricated in cooperation
with the Red Cross Blood Transfusion Service of Upper
Austria, Austrian Cluster for Tissue Regeneration, Linz,
Austria, as a certified medicinal product with growth factor
preservation conditions as previously described [12, 13].
Fibrin glue (Tissucol, Baxter, Vienna, Austria) was used on
the wounds in a spraying technique to avoid shearing off
through manipulation before the membranes were applied
(Figure 3(a)). To avoid irritation by clothes after adaptation of
themembrane to the wound (Figure 3(b)), HAMwas covered
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Figure 3: Application of allogenic human amniotic membrane on a human split-thickness skin-graft donor site defect on the lateral thigh.
(a) Application is conducted in a way such that no air enclosures occur under the membrane. (b) Situation after trimming of the membrane
with an overlapping zone of ∼3 cm on the surrounding skin and fixation with fibrin glue.
by a PU foam (Mepilex, Mölnlycke Health Care, Erkrath,
Germany). This procedure ensured sufficient stability of the
HAM-dressing. In the first control group (𝑛 = 15), the
wounds were covered directly and solely by a PU foam
(Mepilex) (group B). In the second control group (𝑛 = 15),
PU foil (3M Tegaderm Film, 3M, St. Paul, Minnesota, USA)
and consecutive paraffin gauze (Jelonet, Smith & Nephew
GmbH, Marl, Germany) (group C) served as a cover of the
STSG-donor site.
2.2.1. Evaluation of the Wound-Healing Process. The clinical
course was photo-documented on postoperative days 1, 3, 5, 7,
10, 12, 14, and 75 with a digital camera (DMC-FZ4, Panasonic,
Matsushita Electric Industrial Co., Ltd. Osaka, Japan) and by
a data survey questionnaire. The following clinical param-
eters were evaluated: exudation/dryness degree, number of
dressing changes, pain sensation through dressing changes,
pruritus, and dressing comfort. Quantitative assessment cri-
teria were evaluated by two trained examiners on the basis
of the questionnaire as follows: exudation of ichor: 0 = dry, 1
= visible exudate, 2 = moist visible exudate, 3 = wet exudate
visible, and 4 = dripping exudate visible; amount of dressing
changes: overall needed dressing changes; pain sensation:
visual analog pain scale (0 = no pain to 10 = unbearable
pain); pruritus: 0 = no itching, 1 = light, 2 = moderate,
3 = strong, and 4 = very strong. Subjective comfort: 0 =
excellent, 1 = good, 2 = satisfactory, 3 = uncomfortable, and 4
= inacceptable.
2.2.2. Statistical Analysis. IBM SPSS Statistics 19.0 software
(SPSS, Inc., Chicago, IL, USA) was used for statistical
calculations. Differences between the groups in epithelial
thickness, the number of 𝛼-actin-positive myofibroblasts
(𝛼SMA staining), vessels (VWF staining), and the number of
proliferating cells (Ki-67 staining) were analyzed by Student’s
t-test. The means of every clinical parameter of all patients
over all postoperative controls were compared with reference
to the used dressingmaterial. Datawere analyzed as unrelated
measurements by the Mann Whitney U-Test. All 𝑃 values
are given as being two-tailed and are subject to a local
significance level of 5%.
3. Results
3.1. Part A
3.1.1. Clinical Course and Histological Overview. No dif-
ference in the speed of macroscopic wound-healing was
evident between the groups (Figure 4). During postoperative
progress, the two groups showed no differences with regard
to bleeding (slight hemorrhages were observed in both
groups during the first few days after operation), inflamma-
tion, infection, or chronological sequence of wound-healing.
Macroscopic wound contraction measurements revealed no
contraction in either group. In the HAM group, seven
wounds (87.5%) showed a final skin-like color on day 60
(the remaining wound exhibited a pink color), whereas four
wounds (50%) exhibited a skin-like color in the PU group (of
the remaining wounds, 3 were pink, 1 was white).
Histological evaluation of the wound-healing process
by means of HE staining revealed no relevant differences
between the groups; cell infiltration, reepithelialization, and
maturation of the epithelial layers occurred at almost the
same time in the HAM and PU groups.
3.1.2. Epithelial Thickness. Measurement of the epithelial
thickness revealed a significantly broader epithelium in the
HAMgroup on day 7 (𝑃 < 0.001). By contrast, the epithelium
in the HAM group was significantly thinner than in the PU
group on day 60 (𝑃 < 0.001). The epithelium in the HAM
group was thinner on day 60 than on day 7 (𝑃 < 0.001);
epithelial thickness did not change in the PU group between
days 7 and 60 (Table 1).
3.1.3. Immunohistochemical Staining of 𝛼SMA: Wound Con-
traction. No𝛼SMA-positive cells were identified in any of the
specimens of any group because of nonexistent myofibrob-
lasts in the specimens. Accordingly, no statistical comparison
was applicable.
3.1.4. Immunohistochemical Staining of vWF: Neovasculariza-
tion. The number of vessels was significantly higher in the
PU group than in the HAM group on both day 7 and day 10
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(b)
Figure 4: Clinical course of split-thickness skin-graft donor site wounds from days 0 to 60. Upper row shows a representative PU-treated
wound, whereas the lower row shows a representative HAM-treated wound. Note the lack of significant difference in the wound-healing
progress.
Table 1: Epithelial thickness after treatment of split-thickness skin-










membrane 653.3 ± 53.83 190.5 ± 12.24





Table 2: Number of vessels in porcine split-thickness skin-graft
donor sites covered with either human amniotic membrane or
polyurethane foil on postoperative days 7 and 10 (evaluated by




Mean value ± standard error of the mean






membrane 0.90 ± 0.18 1.05 ± 0.14
Polyurethane foil 1.80 ± 0.16 4.70 ± 0.47
(𝑃 < 0.001; Figure 5(a)).The number of vessels was higher on
day 10 than on day 7 within both groups (significant only in
the PUgroup;𝑃 < 0.001). All numbers are detailed inTable 2.
3.1.5. Immunohistochemical Staining of Ki-67: Proliferation.
No difference in proliferation indices was evident between
Table 3: Proliferation indices in samples of split-thickness skin-
graft donor sites treated with human amniotic membrane or
polyurethane foil on postoperative days 7 and 60 (evaluated by
immunohistochemical staining with Ki-67 antibody).
Wound dressing
material







membrane 0.13 ± 0.0023 0.20 ± 0.0051
Polyurethane foil 0.15 ± 0.014 0.29 ± 0.0069
the groups on postoperative days 7 and 60 (Figure 5(b)). The
proliferation index was significantly higher on day 60 within
both groups (Table 3).
3.1.6. Immunohistochemical Staining of Laminin: Forma-
tion of Basement Membrane. Samples of HAM-treated
wounds exhibited a complete basement membrane at day
10 (Figure 5(c)). A comparable integrity of the basement
membrane was not observable until day 20 in the PU group
(Table 4).
3.2. Part B
3.2.1. Clinical Course: Macroscopic Evaluation. The sizes of
the donor sites were between 18 and 32 cm2 and did not differ
significantly between the three groups. Wound-healing was
uneventful in 41 of 45 patients. In 4 patients (1×HAM/PU, 1×
PU, and 2×PU/Gauze), infection of thewoundwas suspected
before postoperative day 12. Treatment was initiated with
topical application of polyhexanide-gel twice a day.







Figure 5: (a) Marking of vascular walls with immunohistochemistry for von Willebrand factor. Polyurethane-dressed wound on the left
and human-amniotic-membrane-dressed wound on the right (300-fold magnification, scale bar: 50 𝜇m) on the tenth postoperative day. The
arrows point exemplarily to vessel walls that are seen as circular structures with a brownish color because of staining with primary and
secondary antibodies. (b) Marking of proliferating cells by immunohistochemistry for Ki-67. Polyurethane-dressed wound on the left and
human-amniotic-membrane-dressed wound on the right (300-fold magnification, scale bar: 50 𝜇m) on the seventh postoperative day. The
arrows point exemplarily to proliferating cells that have a brownish color because of the staining with primary and secondary antibodies. (c)
Marking of a basement membrane by immunohistochemistry for laminin. Polyurethane-dressed wound on the left and human-amniotic-
membrane-dressed wound on the right (300-fold magnification, scale bar: 50 𝜇m) on the tenth postoperative day. Note the complete integrity
of the basement membrane in the HAM example.
In the study group, 93.3% of the wounds were completely
epithelialized on postoperative day 12, whereas 86.7% were
epithelialized in both control groups.This revealed no signif-
icant difference. The macroscopic clinical course of wound-
healing in all three groups is displayed in Figure 6 (donor site
wounds covered with HAM and PU foam (a–c), PU foam
alone (d–f), and PU foil/gauze (g–i) on days 1, 12, and 75; each
row from left to right).
3.2.2. Wound Exudation. Significantly less wound exudation
was found in HAM-treated wounds (𝑛 = 15, group A) com-
pared with the first control group of 𝑛 = 15 wounds covered
directly and solely by a PU foam (Mepilex; group B) and with
the second control group (𝑛 = 15) in which PU foil (3M
Tegaderm Film, 3M, St. Paul, Minnesota, USA) and consec-
utive paraffin gauze (Jelonet, Smith & Nephew GmbH, Marl,
Germany) (group C)served as a cover of the STSG-donor




Figure 6: Clinical course of human split-thickness wounds covered with HAM and PU foam (a–c), PU foam alone (d–f), and PU foil/gauze
(g–i) on days 1, 12, and 75 (each row from left to right).
Table 4: Integrity of basement membrane in split-thickness skin-
graft donor sites treated with human amniotic membrane or with














Basement membrane (±) partly observable; (+) complete.
site (A versus B, A versus C; both 𝑃 < 0.001). No differences
were found regarding the dryness degree between both
control groups (B versus C; 𝑃 = 0.210; Figure 7(a)).
3.2.3. Amount of Dressing Changes. Groups A and B required
fewer dressing changes compared with group C (A versus C
andB versusC; both𝑃 < 0.05). Comparedwith each other, no
significance was evident between groups A and B (𝑃 = 0.332;
Figure 7(b)).
3.2.4. Pain Sensation. Pain sensation during dressing changes
was significantly less in study group B compared with group
A (B versus A and B versus C; both 𝑃 < 0.001). No difference
was evident between groupsA andC (𝑃 = 0.368; Figure 7(c)).
3.2.5. Pruritus. HAM-treated wounds (group A) showed the
slightest pruritus of all groups during the initial phase of
wound-healing (A versus B and A versus C; both 𝑃 < 0.05).
No difference was evident between groups B and C (𝑃 =
0.145; Figure 7(d)).
3.2.6. Comfort. Regarding the comfort of the wound dress-
ings as reported by the patients, the HAM-dressing exceeded
the comfort of both control groups (A versus B and A versus
C; both𝑃 < 0.001). Furthermore, the valuation of the comfort














































Figure 7: Box plot diagrams illustrate the results of a comparison between group A (wounds treated with HAM, 𝑛 = 15), group B (first
control group of 𝑛 = 15 wounds, covered directly and solely by polyurethane foam), and group C (second control group of 𝑛 = 15 wounds in
which polyurethane foil and consecutive paraffin gauze served as a cover of the STSG-donor site). (a) shows the exudation of ichor on a scale
from 0 to 4 (0 = dry; 1 = visible exudate; 2 = moist visible exudate; 3 = wet exudate visible; 4 = dripping exudate visible). (b) shows the overall
required amount of dressing changes during the first 14 postoperative days. (c) shows the relative pain sensation value (visual analog pain
scale: 0 = no pain to 10 = unbearable pain) during dressing changes recorded by the patients. (d) shows the mean of pruritus development
during the first 14 days of wound-healing (0 = no itching; 1 = light; 2 = moderate; 3 = strong; 4 = very strong). (e) shows evaluation of comfort
as reported by the patients (0=excellent; 1 = well; 2 = satisfactory; 3 = uncomfortable; 4 = inacceptable).
in group B was also significantly better evaluated than that in
group C (𝑃 < 0.05; Figure 7(e)).
4. Discussion
STSG are widely applied in all fields of reconstructive surgery
such as skin cancers, burns, and extensive wounding. Under
normal conditions, the donor site heals by reepithelialization
from the dermis (epithelium grows out from hair follicles)
and from surrounding skin but requires dressings for the first
two to three weeks. The ideal dressing for an STSG-donor
site should promote the rate of reepithelialization, control
the exudation to a physiological level, avoid leakages, and be
comfortable for the patient with regard to pain and pruritus
and the number of dressing changes. The postoperative
course of wound-healing significantly depends on the degree
of inflammation and infections. An anti-infective effect of
HAM has been reported [14, 15]. This seems to be a result of
the synthesis of anti-inflammatory proteins and of a reduc-
tion of the expression of transforming growth factor-b (TGF-
b) and proinflammatory cytokines, such as interleukin-10
(IL-10) [14, 16]. Amnion cells synthesize peptides of the innate
immunity system, such as 𝛽-defensins, elastase-inhibitors,
elafin, lactoferrin, or IL-1-RA; these factors might be the
effectors of the antimicrobial capacities of HAM [17, 18]. In
the present study, split-thickness wounds treated with HAM
showed almost no infections, which is in accordance with the
above-mentioned reports demonstrating the anti-infective
capacities of HAM. In addition to its endogenous factors,
another reason responsible for the low rate of infections in
defects covered with HAM might be its capacity of wound
adherence [19].
Analysis of epithelial thickness allows an assessment of
scar hypertrophies. Scars typically develop a few weeks after
trauma and initially show erythroid colorization [20].Within
three to six months, the scar tissue proliferates and increases
in diameter until a steady state is reached. Subsequently, the
scar partially reduces its erythroid colorization and thickness
over a period of about one year [21]. In the animal model
used in this study, measurement of the epithelial thickness in
the STSG wounds revealed a significantly higher epithelium
in the PU group than in the HAM group on postopera-
tive day 60, that is, a tendency for increased cicatrization.
The reduction of cicatrization in the HAM group might
be attributable to its anti-inflammatory capacities and its
previously described accelerating effect on reepithelialization
[4, 14, 16, 19] and to an inhibition of fibrosis [22]. With
respect to the esthetic results in our investigation, HAM-
treated defects in the animal model showed skin-colored
epithelium in more cases (7/8 animals; 87.5%) than in the PU
group (4/8 animals; 50%). A similar tendency was observed
in the clinical part of this study after 72 days of observation.
These findings are of potential clinical relevance. However,
these results will have to be reevaluated/verified in a larger
(multicentered) controlled clinical trial.
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No contractions were observable in any group, either
experimental or clinical. In the animal model, we performed
a quantification ofwound contraction by immunohistochem-
ical staining of 𝛼SMA. The basis for this method is the
finding that 𝛼SMA as an isoform of actin is located within
the cytoskeleton of myofibroblasts and participates in cell
motility. Myofibroblasts are located in healthy tissue and
in pathologically altered tissues; a positive correlation of
their number has been reported in various diseases, such as
Dupuytren’s contracture, and also with the degree of hyper-
trophy in scars [23, 24]. However, no 𝛼SMA-positive cells
were identified within the epithelial layers of any biopsy in
both groups. This is in agreement with the observation of no
wound contractions bymacroscopic evaluation. Accordingly,
an inhibitory effect on wound contractures of HAM cannot
be postulated based on the results of this investigation. Fraser
et al. have reported reduced scar tissue formation and 𝛼SMA
content (analyzed by 𝛼SMA staining) after the treatment of
burn wounds in lambs with HAM (paraffin gauze was used
as a control) [25]. With respect to the present study, this indi-
cates differences between various animal models concerning
the involvement of 𝛼SMA in wound regeneration, an aspect
that should be considered in subsequent investigations.
Another issue that has not yet been sufficiently inves-
tigated is the influence that HAM exerts on angiogenesis,
which is an important factor for the success of numerous sur-
gical interventions and for wound-healing [26]. Irrespective
of the particular pathology, a typical characteristic of chronic
nonhealing wounds is an insufficient blood circulation as
a consequence of the reduced formation of blood vessels.
Hao et al. have reported the expression of thrombospondin-
1, which is an antiangiogenetic protein, in all epithelial and
in ∼20% of the mesenchymal cells of HAM [14]. The authors
have also demonstrated the expression of metalloprotease
inhibitors, TIMP-1, -2, -3, and -4, which also exhibit a
potent antiangiogenetic effect. By contrast, other studies in
which HAM has been used for transplantation have revealed
angiogenetic effects of HAM. For example, the authors of
a study describing the use of HAM for the initial coverage
of chronic leg ulcers before the application of autografts
postulate a proangiogenetic capacity of HAM, because of the
observed accelerated formation of granulating tissue [27, 28].
The experimental part of our study has shown a significantly
lower number of vessels in the HAM group than in the PU
group on postoperative day 5 and on postoperative day 7.
This supports the above-mentioned studies postulating an
antiangiogenetic effect of HAM. The reduced angiogenesis
in the wounds might contribute to the more natural, skin-
like color of the majority of the healed defects in the HAM
group, whereas the denser vascularization in the wounds
treated with polyurethane covers might be one reason for
the pink/erythroid final wound colorization in these groups.
However, further studies focused on this issue need to be
conducted in order to evaluate more extensively angiogenesis
in wounds treated with HAM.
The activation of keratinocytes was evaluated by Ki-67
staining in the animal part of the study in order to determine
the speed of reepithelialization. Ki-67 interacts with a nuclear
antigen synthesized in cells during the G1-, S-, M-, and G2-
phases of the cell cycle and therefore is considered to be
a marker for proliferating cells [29, 30]. During the early
wound-healing process, the activation of keratinocytes plays
a fundamental role in epithelial remodeling [31], with pro-
longed proliferation probably being associated with hyper-
trophic scarring [32]. HAM synthesizes numerous growth
factors such as epithelial growth factor (EGF), keratinocyte
growth factor (KGF), human growth factor (HGF), basic
fibroblast growth factor (bFGF), and tissue growth factors
(TGF-𝛼, TGF-𝛽-1, TGF-𝛽-2, and TGF-𝛽-3) and is assumed
to accelerate reepithelialization and wound-healing by the
activation of keratinocytes [19, 33, 34]. However, no differ-
ences in the rate of reepithelialization between the HAM and
PU groups were seen in the experimental part of our study;
both groups showed a clinically and histologically similar
wound-healing process. Proliferation indices as a marker for
the activation of keratinocytes did not differ between the
groups on the investigated postoperative days. The clinical
part of this study has revealed a nonsignificant difference in
speed of reepithelialization in favor of HAM-treated wounds.
Only a few comparable studies are available. Maral et al.
have demonstrated an accelerated reepithelialization after the
coverage of STSG defects in rats with autologous skin grafts,
with the second-fastest reepithelialization being observed
after coverage with HAM and the slowest healing in the
untreated group [35].
Regular reepithelialization requires not only the closure
of the wound surface but also the complete regeneration of
the basement membrane, which plays a decisive role for the
integrity and functionality of skin. The basement membrane
is mainly composed of collagen type IV and laminin and is
pivotal for coherence between the epithelial and dermal layers
[36]. Andree et al. investigated the formation of the basement
membrane during wound-healing of full-thickness skin-graft
defects in a porcine model. The defects were covered with
various epidermal transplants. The authors demonstrated a
correlation between the transplant materials and the rate of
recreation of the basement membrane [37]. In the animal
model part of this study, we have observed an accelerated
formation of the basement membrane in those wounds
treated with HAM; all defects in this group show a complete
basement membrane on postoperative day 10. By contrast,
only incomplete fragments of the basement membrane are
found in the PU group at this time. These findings might
be explained on the basis of the above-mentioned release of
growth factors by HAM.
The clinical trial further revealed that dressing changes
were perceived as being more painful when wounds were
treatedwithHAM-PU/gauze thanwhenwoundswere treated
with PU foam without HAM. Significantly reduced wound
exudation, less pruritus, and fewer dressing changes (with the
highest subjective comfort) were observed in HAM-treated
wounds. These results are in accordance with a study by
Branski et al. who covered partial-thickness (second degree)
burns in children with either HAM or topical antimicrobials;
the patients in the amnion group needed significantly fewer
dressing changes, but the rate of infections between the
groups was not different [38].
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We need to clarify whether HAM can be standardized
for clinical use. The material can indeed be standardized by
applying protocols provided by certified tissue banks. How-
ever, various culture or cryopreservation techniques are still
under investigation [13, 39, 40]. For example, a quality check
of each placenta for the HAM used in this study was carried
out, and only avascular HAM areas were processed. HAM
can further be standardized with respect to the selection
of donors (e.g., exclusion of HIV-positive donors) and the
testing of thematerial for infectious agents (e.g., agglutination
tests for HIV (anti-HIV), HEP-C (anti-HCV), HEP-B (anti-
HBc, HB-Ag), CMV (anti-CMV-IgG/-IgM), and TPHA- and
ELISA-tests for syphilis and polymerase chain reaction tests
for HIV, HCV, and HPV). As a consequence, we can assume
that wound-healing should not be different between patients
when standardized HAM is used for the treatment of similar
defects, and the probability of disease transmissions should
be similar to that of other allogeneic grafts such as blood cell
concentrates.
Although HAM did not exceed the qualities of conven-
tional materials to a relevant degree, it has shown almost
equal characteristics. Previous studies have described HAM
as a cost-effective treatment of burn wounds for developing
countries [41, 42]. Accordingly, HAM might also be used as
an economically reasonable alternative biomaterial for the
treatment of STSG-donor sites in developing countries. HAM
can be harvested and stored in any country fulfilling the
following requirements: abdominal caesarean sections have
to be carried out, and sterile conditions for the processing and
storage of HAMmust be available. To avoid ethical conflicts,
institutional review board or ethics committee approval
should be obtained, and local legal regulations should be met
prior to the medical use of HAM. Being an allogeneic graft,
similar to blood cell concentrates, no ethical concerns should
be raised against the use of HAM in specific countries, as
long as other allogeneic graft products are also used in clinical
routine.
5. Conclusions
In view of the above-mentioned findings obtained in the
animal model study and the clinical trial, treatment with
HAM as a wound dressing for split-thickness wounds seems
to result in improved esthetic results and in less hypertrophic
scarring when compared with treatment with conventional
PU-covered wounds during the first 75 days of wound-
healing. Although no significant difference in the overall
speed of reepithelialization is evident in this investigation, the
accelerated reformation of the basement membrane might
result in improved defensive capacities of the wound against
microbial infections, since the basement membrane forms
a line of resistance, even if the overlying epithelial layer is
not complete. This should be investigated in further studies.
The results of this combined experimental and prospective
clinical trial reveal that HAM is a well-performing wound
dressing for STSG-donor sites with statistically significant but
clinically only minor (or even not relevant) advantages when
compared with the commonly used PU dressings. However,
HAMmight be a cost-effective alternative wound dressing for
STSG-donor sites in developing countries.
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